Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: TG4001

    Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

    TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001

    Published 2 November 2022
    Categorized as 2022, 2022, Press release, dates, Invir.IO, Press release, TG4001, TG4001

    R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

    TRANSGENE R&D DAY

    Published 27 September 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

    First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers

    20210624 Transgene TG4001.12 FPI EN

    Published 24 June 2021
    Categorized as 2021, Press release, TG4001, TG4001

    Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

    20210310 Transgene TG4001 randomized Phase II EN

    Published 10 March 2021
    Categorized as 2021, Press release, TG4001, TG4001

    Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC

    Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication

    Published 26 January 2021
    Categorized as 2021, Publication, TG4001, TG4001

    Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

    20201203 – TG4001 mini oral prez ESMO IO EN

    Published 3 December 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

    20201109 – TG4001+avelumab presentation poster SITC – EN

    Published 9 November 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

    20201027 – TG4001+avelumab abstract data SITC – EN

    Published 27 October 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

    20201019 TG4001+avelumab SITC – EN

    Published 19 October 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers

    CP TG4001+avelumab EN – Vdef-

    Published 22 July 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Posts navigation

    Page 1 Page 2 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo